Cargando…
Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial
CONTEXT: Acetyl-l-carnitine (ALC), a mitochondrial carrier involved in lipid oxidation and glucose metabolism, decreased systolic blood pressure (SBP), and ameliorated insulin sensitivity in hypertensive nondiabetic subjects at high cardiovascular risk. OBJECTIVE: To assess the effects of ALC on SBP...
Autores principales: | Parvanova, Aneliya, Trillini, Matias, Podestà, Manuel A, Iliev, Ilian P, Aparicio, Carolina, Perna, Annalisa, Peraro, Francesco, Rubis, Nadia, Gaspari, Flavio, Cannata, Antonio, Ferrari, Silvia, Bossi, Antonio C, Trevisan, Roberto, Parameswaran, Sreejith, Chávez-Iñiguez, Jonathan S, Masnic, Fahrudin, Seck, Sidy Mohamed, Jiamjariyaporn, Teerayuth, Cortinovis, Monica, Perico, Luca, Sharma, Kanishka, Remuzzi, Giuseppe, Ruggenenti, Piero, Warnock, David G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912091/ https://www.ncbi.nlm.nih.gov/pubmed/29696241 http://dx.doi.org/10.1210/js.2017-00426 |
Ejemplares similares
-
Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study
por: Ruggenenti, Piero, et al.
Publicado: (2021) -
Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
por: Ruggenenti, Piero, et al.
Publicado: (2008) -
Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes
por: Ruggenenti, Piero, et al.
Publicado: (2012) -
Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A prospective randomized double-blind clinical trial
por: Ruggenenti, Piero, et al.
Publicado: (2010) -
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
por: Perico, Norberto, et al.
Publicado: (2019)